Endocrine side effects during cancer treatment. Lecture for practitioners

Endocrine side effects during cancer treatment. Lecture for practitioners

Targeted therapy and immune checkpoint inhibitors (ICI) are increasingly being used to treat many solid tumors. The use alpelisib and ICPI has a risk of side-effects, particularly endocrine dysfunctions. In this lecture, there are clearly stated: initial screening, monitoring, selection of therapy a...

Full description

Bibliographic Details
Main Authors:	Anastasiya A. Glibka, Natalya V. Mazurina, Ekaterina A. Troshina
Format:	Article
Language:	Russian
Published:	ZAO "Consilium Medicum" 2022-08-01
Series:	Consilium Medicum
Subjects:	hyperglycemia destructive thyroiditis hypophysitis alpelisib immune checkpoint inhibitors
Online Access:	https://consilium.orscience.ru/2075-1753/article/viewFile/109885/84128

Similar Items

Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy
by: A. A. Glibka, et al.
Published: (2024-04-01)

Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
by: Won Sang Yoo, et al.
Published: (2023-12-01)

Endocrine side effects of immune checkpoint inhibitors
by: Zulma Cardona, et al.
Published: (2023-05-01)

Endocrine adverse events of immune checkpoint inhibitors: results of a single-center study
by: E. V. Poddubskaya, et al.
Published: (2019-12-01)

Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature
by: Christine Newman, et al.
Published: (2021-02-01)

Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients
by: Fouad Mitri, et al.
Published: (2024-03-01)

Immune-related endocrine disorders in novel immune checkpoint inhibition therapy
by: Le Min
Published: (2016-12-01)

Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists
by: Irena Druce, et al.
Published: (2022-07-01)

Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review
by: Sara Menotti, et al.
Published: (2023-07-01)

The autoimmune IgG4 -associated endocrine pathology
by: Marina Yu. Yukina, et al.
Published: (2017-11-01)

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
by: Natalya V. Mazurina, et al.
Published: (2021-02-01)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
by: Margot Stagnetto, et al.
Published: (2020-11-01)

Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?
by: Agnese Barnabei, et al.
Published: (2022-03-01)

Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
by: Jingli Lu, et al.
Published: (2019-12-01)

Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review
by: Agnese Barnabei, et al.
Published: (2020-12-01)

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis
by: LI Jia-yi, XING Bing
Published: (2020-03-01)

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
by: Tory Starzyk, MA, et al.
Published: (2022-01-01)

Hypophysitis: Defining Histopathologic Variants and a Review of Emerging Clinical Causative Entities
by: Cameron A. Rawanduzy, et al.
Published: (2023-03-01)

Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer – A Real-Life Experience
by: Percik R, et al.
Published: (2023-05-01)

Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
by: Sahityasri Thapi, et al.
Published: (2019-09-01)

Development of three endocrinopathies under nivolumab therapy
by: Anastasia A. Glibka, et al.
Published: (2023-02-01)

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
by: Maria Stelmachowska-Banaś, et al.
Published: (2020-10-01)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
by: Stavroula A. Paschou, et al.
Published: (2022-03-01)

Correction of endocrine complications of oncoimmunotherapy
by: E. A. Pigarova, et al.
Published: (2023-04-01)

Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors
by: Anastasiya A. Glibka, et al.
Published: (2022-10-01)

IgG4-related disease in endocrine practice
by: Agata Rzepecka, et al.
Published: (2018-12-01)

Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors
by: Shintaro Iwama, et al.
Published: (2021-04-01)

Immunotherapy-Associated Hypothyroidism: Comparison of the Pre-Existing With De-Novo Hypothyroidism
by: Megan M. Kristan, et al.
Published: (2022-03-01)

Unexpected cure of a toxic nodule in a multinodular goiter induced by immune checkpoint inhibitors: a case report
by: Hippolyte Dupuis, et al.
Published: (2023-01-01)

Lesions in endocrine glands as a complication of immunotherapy in the practice of oncologist
by: Nurana F. Nuralieva, et al.
Published: (2019-04-01)

Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors—A Single-Center Study
by: Anna Lea Amylidi, et al.
Published: (2023-12-01)

Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle
by: Agnese Barnabei, et al.
Published: (2022-02-01)

Alpelisib-induced thyroiditis in a patient with metastatic breast cancer: Is routine monitoring of thyroid function required?
by: Calvin R Flynn, et al.
Published: (2023-03-01)

Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report
by: Yi Feng, et al.
Published: (2022-04-01)

Steroid Responsive Xanthomatous Hypophysitis Associated with Autoimmune Thyroiditis: A Case Report
by: Ji Young Joung, et al.
Published: (2013-03-01)

Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report
by: Fumi Kikuchi, et al.
Published: (2021-04-01)

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
by: Nicia I. Profili, et al.
Published: (2023-08-01)

Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic–pituitary–adrenal axis abnormalities: a clinical case
by: Yixi Bi, et al.
Published: (2023-01-01)

Progress in Diagnosis and Treatment of Autoimmune Hypophysitis
by: ZHAI Xiao, et al.
Published: (2022-01-01)

Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis
by: Piaohong Chen, et al.
Published: (2023-05-01)